USA – The FDA has temporarily halted trials of Gilead Sciences’ anti-CD47 antibody magrolimab in combination with azacitidine, citing an “apparent imbalance” in investigator-reported suspected unexpected serious adverse reactions (SUSARs)…
Read MoreFDA issues partial hold affecting Gilead’s Magrolimab, an investigational monoclonal antibody
